Proteolytic enzyme and adiponectin receptors as potential targets for COVID-19 therapy
Open Access
- 14 May 2021
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (3), 2791
- https://doi.org/10.15829/1728-8800-2021-2791
Abstract
The coronavirus disease 2019 (COVID-19) pandemic requires not only the creation of vaccines to prevent the spread of the disease, but also the development of novel drugs aimed at reducing viral load, suppressing an excessive immune response and preventing the severe complications such as lung fibrosis and acute respiratory distress syndrome. One of the promising targets for studying the development of pneumonia, systemic inflammation and disseminated intravascular coagulation in COVID-19 is the plasminogen activator system. In patients with a severe disease course, impaired activity or expression of plasminogen activators significantly increases the blood level of D-dimer and fibrinogen, as well as correlates with intravascular coagulation and thrombus formation. The second promising target for studying the pathogenesis of COVID-19 is the adiponectin/T-cadherin system: adiponectin is able to reduce the content of pro-inflammatory cytokines, the increase of which is characteristic of COVID-19, and stimulate the production of an anti-inflammatory cytokine interleukin-10. The review describes the role of plasminogen and T-cadherin activators in their possible participation in the development of pulmonary fibrosis in COVID-19 and hemostasis regulation, as well as cardio- and vasculoprotective function of adiponectin and its receptor, T-cadherin.Keywords
This publication has 35 references indexed in Scilit:
- ACE2: the molecular doorway to SARS-CoV-2Cell & Bioscience, 2020
- COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment optionsCardiovascular Research, 2020
- Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trialPublished by Cold Spring Harbor Laboratory ,2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathologySeminars in Immunopathology, 2017
- SARS and MERS: recent insights into emerging coronavirusesNature Reviews Microbiology, 2016
- DNA damaging agent-induced apoptosis is regulated by MCL-1 phosphorylation and degradation mediated by the Noxa/MCL-1/CDK2 complexOncotarget, 2016
- Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditionsCytokine, 2015
- Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up StudyThe Journal of Immunology, 2011